Search Results 901-910 of 17204 for monoclonal antibody

1. A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma - Mayo Clinic

   ... monoclonal antibody, daratumumab + bortezomib/thalidomide/dexamethasone \[D-VTd\] and daratumumab + bortezomib/ lenalidomide/dexamethasone \[D-VRd\]), or ...

2. Study of DF9001 in Patients With Advanced Solid Tumors - Mayo Clinic

   ... antibody, administered ... - History of or ongoing pulmonary fibrosis or interstitial lung disease. 10. Known severe hypersensitivity reactions to monoclonal ...

3. A Study of LY2951742 for Patients with Episodic Cluster Headaches - Mayo Clinic

   ... antibody to the CGRP receptor, or antibody to nerve ... Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins ...

4. Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma (SEQUEL) - Mayo Clinic

   ... monoclonal antibody or hypersensitivity to pembrolizumab or any of its excipients. * Has had a prior anti-cancer monoclonal antibody (mAb), excluding anti ...

5. Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer - Mayo Clinic

   ... antibody Patients in Expansion Phase, Cohorts 2 and 3; Previously ... Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to baseline ...

6. A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma - Mayo Clinic

   Monoclonal antibodies within 28 days; Corticosteroid administration >20 mg/day of prednisone or equivalent within 14 days; Proteasome inhibitors within 14 ...

7. A Study of the Safety and Effectiveness of GS-5745 in Participants with Moderately to Severely Active Crohn's Disease - Mayo Clinic

   Treatment with any monoclonal antibody within 4 weeks of screening; History or evidence of colonic mucosal dysplasia; HIV, hepatitis B, hepatitis C, or ...

8. A Study to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors - Mayo Clinic

   Previous NY-ESO-1 vaccine or NY-ESO-1 targeting antibody. ... Participant has received immune therapy (monoclonal antibody therapy, checkpoint inhibitors) within ...

9. Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab - Mayo Clinic

   The purpose of this study is to evaluate T cell and antibody immunity in patients with HER2+ breast cancer who will receive trastuzumab with standard ...

10. Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary - Mayo Clinic

    ... monoclonal antibody or hypersensitivity to pembrolizumab or any of its excipients. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks ...